Extracellular Vesicles Released from Human Umbilical Cord-Derived Mesenchymal Stromal Cells Prevent Life-Threatening Acute Graft-Versus-Host Disease in a Mouse Model of Allogeneic Hematopoietic Stem Cell Transplantation

Stem Cells and Development

Volumn 25, Issue 24, 2016, Pages 1874-1883

  Wang, Li ^a,b   Gu, Zhenyang ^a   Zhao, Xiaoli ^c   Yang, Nan ^a   Wang, Feiyan ^a   Deng, Ailing ^a   Zhao, Shasha ^a   Luo, Lan ^a   Wei, Huaping ^a   Guan, Lixun ^a   Gao, Zhe ^a   Li, Yonghui ^a   Wang, Lili ^a   Liu, Daihong ^a   Gao, Chunji ^a  

^a GENERAL HOSPITAL OF NORTHERN THEATER COMMAND   (China)

^b 401 Hospital of PLA   (China)

^c PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

exosomes; extracellular vesicles; graft versus host disease; hematopoietic stem cell transplantation; Mesenchymal stromal cells; microvesicles

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 2; TUMOR NECROSIS FACTOR; AUTACOID; CYTOKINE; LEUKOCYTE ANTIGEN;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; EXOSOME; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOASSAY; IN VITRO STUDY; IN VIVO STUDY; MALE; MESENCHYMAL STROMA CELL; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN BLOOD LEVEL; SPLEEN CELL; TARGET ORGAN; UMBILICAL CORD BLOOD; ACUTE DISEASE; ADVERSE EFFECTS; ALLOTRANSPLANTATION; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CYTOLOGY; DISEASE MODEL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE COUNT; METABOLISM; PATHOLOGY; SECRETION (PROCESS); T LYMPHOCYTE; UMBILICAL CORD;

ACUTE DISEASE; ANIMALS; ANTIGENS, CD; CYTOKINES; DISEASE MODELS, ANIMAL; EXTRACELLULAR VESICLES; FLOW CYTOMETRY; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSION; INFLAMMATION MEDIATORS; LYMPHOCYTE COUNT; MALE; MESENCHYMAL STROMAL CELLS; MICE, INBRED BALB C; MICE, INBRED C57BL; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS; UMBILICAL CORD;

EID: 85003794076     PISSN: 15473287     EISSN: 15578534     Source Type: Journal    
DOI: 10.1089/scd.2016.0107     Document Type: Article

References (48)

1. Holtan SG, M Pasquini and DJ Weisdorf. (2014). Acute graft-versus-host disease: a bench-to-bedside update. Blood 124:363-373.
2. von Dalowski F, M Kramer, M Wermke, R Wehner, C Rollig, N Alakel, F Stolzel, S Parmentier, K Sockel, et al. (2016). Mesenchymal stromal cells for treatment of acute steroid-refractory GvHD: clinical responses and long-term outcome. Stem Cells 34:357-366.
3. Ferrara JL, JE Levine, P Reddy and E Holler. (2009). Graftversus-host disease. Lancet 373:1550-1561.
4. Le Blanc K and D Mougiakakos. (2012). Multipotent mesenchymal stromal cells and the innate immune system. Nat Rev Immunol 12:383-396.
5. Bernardo ME, LM Ball, AM Cometa, H Roelofs, M Zecca, MA Avanzini, A Bertaina, L Vinti, A Lankester, et al. (2011). Co-infusion of ex vivo-expanded, parental MSCs prevents life-threatening acute GVHD, but does not reduce the risk of graft failure in pediatric patients undergoing allogeneic umbilical cord blood transplantation. Bone Marrow Transplant 46:200-207.
6. Baron F, C Lechanteur, E Willems, F Bruck, E Baudoux, L Seidel, JF Vanbellinghen, K Hafraoui, M Lejeune, et al. (2010). Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLAmismatched allogeneic transplantation following nonmyeloablative conditioning. Biol Blood Marrow Transplant 16:838-847.
7. Kuzmina LA, NA Petinati, EN Parovichnikova, LS Lubimova, EO Gribanova, TV Gaponova, IN Shipounova, OA Zhironkina, AE Bigildeev, et al. (2012). Multipotent mesenchymal stromal cells for the prophylaxis of acute graftversus-host disease-a phase II study. Stem Cells Int 2012: 968213.
8. Introna M, G Lucchini, E Dander, S Galimberti, A Rovelli, A Balduzzi, D Longoni, F Pavan, F Masciocchi, et al. (2014). Treatment of graft versus host disease with mesenchymal stromal cells: a phase I study on 40 adult and pediatric patients. Biol Blood Marrow Transplant 20:375-381.
9. Le Blanc K, F Frassoni, L Ball, F Locatelli, H Roelofs, I Lewis, E Lanino, B Sundberg, ME Bernardo, et al. (2008). Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 371:1579-1586.
10. Zhao K, R Lou, F Huang, Y Peng, Z Jiang, K Huang, X Wu, Y Zhang, Z Fan, et al. (2015). Immunomodulation effects of mesenchymal stromal cells on acute graft-versushost disease after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 21:97-104.
11. Lee SH, MW Lee, KH Yoo, DS Kim, MH Son, KW Sung, H Cheuh, SJ Choi, W Oh, YS Yang and HH Koo. (2013). Co-transplantation of third-party umbilical cord bloodderived MSCs promotes engraftment in children undergoing unrelated umbilical cord blood transplantation. Bone Marrow Transplant 48:1040-1045.
12. Le Blanc K, H Samuelsson, B Gustafsson, M Remberger, B Sundberg, J Arvidson, P Ljungman, H Lonnies, S Nava and O Ringden. (2007). Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Leukemia 21:1733-1738.
13. Liu K, Y Chen, Y Zeng, L Xu, D Liu, H Chen, X Zhang, W Han, Y Wang, et al. (2011). Coinfusion of mesenchymal stromal cells facilitates platelet recovery without increasing leukemia recurrence in haploidentical hematopoietic stem cell transplantation: a randomized, controlled clinical study. Stem Cells Dev 20:1679-1685.
14. de Lima M, I McNiece, SN Robinson, M Munsell, M Eapen, M Horowitz, A Alousi, R Saliba, JD McMannis, et al. (2012). Cord-blood engraftment with ex vivo mesenchymalcell coculture. N Engl J Med 367:2305-2315.
15. Haarer J, CL Johnson, Y Soeder and MH Dahlke. (2015). Caveats of mesenchymal stem cell therapy in solid organ transplantation. Transpl Int 28:1-9.
16. Forslow U, O Blennow, K LeBlanc, O Ringden, B Gustafsson, J Mattsson and M Remberger. (2012). Treatment with mesenchymal stromal cells is a risk factor for pneumoniarelated death after allogeneic hematopoietic stem cell transplantation. Eur J Haematol 89:220-227.
17. EL Andaloussi S, I Mager, XO Breakefield and MJ Wood. (2013). Extracellular vesicles: biology and emerging therapeutic opportunities. Nat Rev Drug Discov 12:347-357.
18. Bruno S, C Grange, MC Deregibus, RA Calogero, S Saviozzi, F Collino, L Morando, A Busca, M Falda, et al. (2009). Mesenchymal stem cell-derived microvesicles protect against acute tubular injury. J Am Soc Nephrol 20:1053-1067.
19. Lai RC, F Arslan, MM Lee, NS Sze, A Choo, TS Chen, M Salto-Tellez, L Timmers, CN Lee, et al. (2010). Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury. Stem Cell Res 4:214-222.
20. Xin H, Y Li, Y Cui, JJ Yang, ZG Zhang and M Chopp. (2013). Systemic administration of exosomes released from mesenchymal stromal cells promote functional recovery and neurovascular plasticity after stroke in rats. J Cereb Blood Flow Metab 33:1711-1715.
21. Zhu YG, XM Feng, J Abbott, XH Fang, Q Hao, A Monsel, JM Qu, MA Matthay and JW Lee. (2014). Human mesenchymal stem cell microvesicles for treatment of Escherichia coli endotoxin-induced acute lung injury in mice. Stem Cells 32:116-125.
22. Lee C, SA Mitsialis, M Aslam, SH Vitali, E Vergadi, G Konstantinou, K Sdrimas, A Fernandez-Gonzalez and S Kourembanas. (2012). Exosomes mediate the cytoprotective action of mesenchymal stromal cells on hypoxia-induced pulmonary hypertension. Circulation 126:2601-2611.
23. Li T, Y Yan, B Wang, H Qian, X Zhang, L Shen, M Wang, Y Zhou, W Zhu, W Li and W Xu. (2013). Exosomes derived from human umbilical cord mesenchymal stem cells alleviate liver fibrosis. Stem Cells Dev 22:845-854.
24. Zhang B, M Wang, A Gong, X Zhang, X Wu, Y Zhu, H Shi, L Wu, W Zhu, H Qian and W Xu. (2014). HucMSCexosome mediated-Wnt4 signaling is required for cutaneous wound healing. Stem Cells 33:2158-2168.
25. Kordelas L, V Rebmann, AK Ludwig, S Radtke, J Ruesing, TR Doeppner, M Epple, PA Horn, DW Beelen and B Giebel. (2014). MSC-derived exosomes: a novel tool to treat therapy-refractory graft-versus-host disease. Leukemia 28:970-973.
26. Zhang J, J Guan, X Niu, G Hu, S Guo, Q Li, Z Xie, C Zhang and Y Wang. (2015). Exosomes released from human induced pluripotent stem cells-derived MSCs facilitate cutaneous wound healing by promoting collagen synthesis and angiogenesis. J Transl Med 13:49.
27. Colombo M, G Raposo and C Thery. (2014). Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol 30: 255-289.
28. Wang H, RT Sun, Y Li, YF Yang, FJ Xiao, YK Zhang, SX Wang, HY Sun, QW Zhang, CT Wu and LS Wang. (2015). HGF gene modification in mesenchymal stem cells reduces radiation-induced intestinal injury by modulating immunity. PLoS One 10:e0124420.
29. Ekstrom K, O Omar, C Graneli, X Wang, F Vazirisani and P Thomsen. (2013). Monocyte exosomes stimulate the osteogenic gene expression of mesenchymal stem cells. PLoS One 8:e75227.
30. Wu S, GQ Ju, T Du, YJ Zhu and GH Liu. (2013). Microvesicles derived from human umbilical cord Wharton's jelly mesenchymal stem cells attenuate bladder tumor cell growth in vitro and in vivo. PLoS One 8:e61366.
31. Gao L, F Liu, L Tan, T Liu, Z Chen and C Shi. (2014). The immunosuppressive properties of non-cultured dermalderived mesenchymal stromal cells and the control of graftversus-host disease. Biomaterials 35:3582-3588.
32. Cooke KR, L Kobzik, TR Martin, J Brewer, J Delmonte, Jr., JM Crawford and JL Ferrara. (1996). An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin. Blood 88:3230-3239.
33. Zhang C, XH Chen, X Zhang, L Gao, PY Kong, XG Peng, X Liang, L Gao, Y Gong and QY Wang. (2011). Human umbilical cord blood-derived stromal cells, a new resource in the suppression of acute graft-versus-host disease in haploidentical stem cell transplantation in sublethally irradiated mice. J Biol Chem 286:13723-13732.
34. Kanada M, MH Bachmann, JW Hardy, DO Frimannson, L Bronsart, A Wang, MD Sylvester, TL Schmidt, RL Kaspar, et al. (2015). Differential fates of biomolecules delivered to target cells via extracellular vesicles. Proc Natl Acad Sci USA 112:E1433-E1442.
35. Lotvall J, AF Hill, F Hochberg, EI Buzas, D Di Vizio, C Gardiner, YS Gho, IV Kurochkin, S Mathivanan, et al. (2014). Minimal experimental requirements for definition of extracellular vesicles and their functions: a position statement from the International Society for Extracellular Vesicles. J Extracell Vesicles 3:26913.
36. Martin PJ, JP Uberti, RJ Soiffer, H Klingemann, EK Waller, AS Daly, RP Herrmann and P Kebriaei. (2010). Prochymal improves response rates in patients with Steroid Refractory acute Graft Versus Host Disease (SR-GVHD) involving the liver and GUT: results of a randomized, placebo-controlled, multicenter phase III trial in GVHD. Biol Blood Marrow Transpl 16:S169-S170.
37. Galipeau J. (2013). The mesenchymal stromal cells dilemma-does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versushost disease represent a death knell or a bump in the road? Cytotherapy 15:2-8.
38. McGuirk JP, JR Smith, CL Divine, M Zuniga and ML Weiss. (2015). Wharton's jelly-derived mesenchymal stromal cells as a promising cellular therapeutic strategy for the management of graft-versus-host disease. Pharmaceuticals (Basel) 8:196-220.
39. Najar M, G Raicevic, HI Boufker, H Fayyad Kazan, C De Bruyn, N Meuleman, D Bron, M Toungouz and L Lagneaux. (2010). Mesenchymal stromal cells use PGE2 to modulate activation and proliferation of lymphocyte subsets: combined comparison of adipose tissue, Wharton's Jelly and bone marrow sources. Cell Immunol 264:171-179.
40. Zhang B, Y Yin, RC Lai, SS Tan, AB Choo and SK Lim. (2014). Mesenchymal stem cells secrete immunologically active exosomes. Stem Cells Dev 23:1233-1244.
41. Amarnath S, JE Foley, DE Farthing, RE Gress, A Laurence, MA Eckhaus, JY Metais, JJ Rose, FT Hakim, et al. (2015). Bone marrow-derived mesenchymal stromal cells harness purinergenic signaling to tolerize human Th1 cells in vivo. Stem Cells 33:1200-1212.
42. Chen W, Y Huang, J Han, L Yu, Y Li, Z Lu, H Li, Z Liu, C Shi, F Duan and Y Xiao. (2016). Immunomodulatory effects of mesenchymal stromal cells-derived exosome. Immunol Res 64:831-840.
43. Zou X, G Zhang, Z Cheng, D Yin, T Du, G Ju, S Miao, G Liu, M Lu and Y Zhu. (2014). Microvesicles derived from human Wharton's Jelly mesenchymal stromal cells ameliorate renal ischemia-reperfusion injury in rats by suppressing CX3CL1. Stem Cell Res Ther 5:40.
44. Conforti A, M Scarsella, N Starc, E Giorda, S Biagini, A Proia, R Carsetti, F Locatelli and ME Bernardo. (2014). Microvescicles derived from mesenchymal stromal cells are not as effective as their cellular counterpart in the ability to modulate immune responses in vitro. Stem Cells Dev 23:2591-2599.
45. Gouveia de Andrade AV, G Bertolino, J Riewaldt, K Bieback, J Karbanova, M Odendahl, M Bornhauser, M Schmitz, D Corbeil and T Tonn. (2015). Extracellular vesicles secreted by bone marrow-and adipose tissuederived mesenchymal stromal cells fail to suppress lymphocyte proliferation. Stem Cells Dev 24:1374-1376.
46. Wegmeyer H, AM Broske, M Leddin, K Kuentzer, AK Nisslbeck, J Hupfeld, K Wiechmann, J Kuhlen, C von Schwerin, et al. (2013). Mesenchymal stromal cell characteristics vary depending on their origin. Stem Cells Dev 22:2606-2618.
47. Kourembanas S. (2015). Exosomes: vehicles of intercellular signaling, biomarkers, and vectors of cell therapy. Annu Rev Physiol 77:13-27.
48. Yeo RW, RC Lai, B Zhang, SS Tan, Y Yin, BJ Teh and SK Lim. (2013). Mesenchymal stem cell: an efficient mass producer of exosomes for drug delivery. Adv Drug Deliv Rev 65:336-341.